TY  - JOUR
AU  - Klostermann, A.
AU  - Debertshäuser, T.
AU  - Benary, M.
AU  - Biernath, N.
AU  - Erber, B.
AU  - Tahbaz, R.
AU  - Möbs, M.
AU  - Joosten, M.
AU  - Schmitt, W. D.
AU  - Kim, T.
AU  - Jelas, I.
AU  - Chai, L.
AU  - Jegodka, Y.
AU  - Keller, U.
AU  - Beule, D.
AU  - Ochsenreither, S.
AU  - De Santis, M.
AU  - Schlomm, T.
AU  - Keilholz, Ulrich
AU  - Knödler, M.
AU  - Rieke, Damian
TI  - Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers.
JO  - ESMO open
VL  - 10
IS  - 7
SN  - 2059-7029
CY  - [London]
PB  - Elsevier
M1  - DKFZ-2025-01346
SP  - 105497
PY  - 2025
AB  - Outcome is dismal in patients with advanced genitourinary (GU) cancers refractory to standard treatments. Molecular analyses and subsequent discussion of cases in specialized molecular tumor boards (MTBs) are increasingly incorporated into clinical management to facilitate personalized treatment. Data on this approach are lacking for GU malignancies.We conducted a retrospective analysis of patients with GU cancers discussed in the MTB at the Charité between 2016 and 2023. Ethics approval was obtained for prospective follow-up of patients after written informed consent and for retrospective data analysis. Clinical benefit was defined as complete response (CR), partial response (PR) or stable disease (SD) >6 months or a progression-free survival (PFS) ratio between molecularly matched therapy (MMT) and previous non-MMT >1.3. Outcome was assessed by the investigators.Among 126 identified MTB patients, most patients had a rare tumor type (n = 59), followed by adenocarcinoma of the prostate (n = 45), urothelial carcinoma (n = 17) and clear-cell renal carcinoma (n = 5). Molecular profiling included immunohistochemistry (n = 80), panel sequencing (n = 110) and/or whole-exome/-transcriptome sequencing (n = 21). Eleven patients died before the final MTB discussion. At least one treatment option for MMT was identified for 78/115 patients (68
KW  - genitourinary cancer (Other)
KW  - molecular tumor board (Other)
KW  - precision oncology (Other)
KW  - real-world data (Other)
KW  - targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40602108
DO  - DOI:10.1016/j.esmoop.2025.105497
UR  - https://inrepo02.dkfz.de/record/302806
ER  -